Shanghai Renews Centralized Drug Procurement Contracts for Third Quarter

Shanghai, Aug 24, 2026 — Shanghai’s Medical Procurement Center said it will renew centralized volume-based procurement contracts for selected drugs in the third quarter of 2026, extending agreements with winning manufacturers and their designated distributors after initial purchase volumes were fulfilled.

Policy Snapshot

AttributeDetail
IssuerShanghai Medical Centralized Bidding and Procurement Affairs Management Center
DocumentNotice on the Renewal of Selected Drugs in Centralized Procurement (Q3 2026)
Effective dateSept 20, 2026
ScopeSelected drugs with expired procurement agreements and completed contracted volumes
ActionRenewal of tripartite purchase agreements among procurement center, winning manufacturers, and designated distributors

Key Provisions

  • Automatic renewal trigger — Contracts are extended for drugs that have reached the end of their initial procurement cycle and satisfied contracted purchase volumes under the volume-based procurement framework.
  • Tripartite structure — The procurement center will sign renewed purchase agreements directly with winning enterprises and their appointed distribution partners.
  • Complaint channel — Medical institutions are instructed to report any procurement issues to the procurement center during the renewal process.
  • Residual compliance — Unspecified matters will be governed by existing centralized procurement regulations and the terms of the tripartite agreements.

Market Impact Analysis

The renewal notice underscores Shanghai’s commitment to maintaining supply continuity under its volume-based procurement regime, a national pricing reform that has slashed drug costs by forcing manufacturers to bid aggressively for hospital market share. By automatically extending contracts for drugs that hit volume targets, regulators are signaling stability to winning suppliers while preventing supply disruptions that could arise from abrupt re-tendering.

For pharmaceutical companies, the renewal mechanism reduces regulatory uncertainty for products that have already secured centralized procurement slots, allowing them to plan production and distribution without navigating fresh bidding rounds. However, the notice also implicitly tightens compliance expectations—manufacturers must have fulfilled contracted volumes to qualify, penalizing those that struggled with supply or quality during the initial term.

Forward-Looking Statement

Industry observers expect the Q3 renewal wave to proceed without major disruption, given that eligible drugs have already demonstrated supply reliability. The Sept 20 effective date aligns with Shanghai’s typical procurement calendar, suggesting seamless transitions for hospital formularies. Looking ahead, the renewal template is likely to be replicated in other provincial procurement platforms as volume-based procurement contracts signed during the 2024-2025 national expansion cycle begin maturing, potentially triggering a broader wave of contract extensions across China’s public hospital network in 2027.-China Health Reform Pulse

Policy Source: https://www.smpaa.cn/xxgk/gggs/2026/08/24/24042.shtml

China Expands Family Doctor Network, Pushes Digital Health in Primary Care

Beijing, Aug 18, 2026 — China’s National Health Commission, National Administration of Traditional Chinese Medicine, and National Disease Control Administration jointly issued a 10-point directive to overhaul family doctor contract services, expanding coverage from grassroots clinics to tier-two and tier-three public hospitals and private facilities while mandating artificial intelligence integration and wearable health devices across primary care networks by 2030.

Policy Snapshot

AttributeDetail
IssuersNHC General Office; NATCM General Office; NDCA General Office
DocumentNotice on Deepening “Six Expansions” to Solidify Family Doctor Contract Services
File No.Guo Wei Ban Ji Ceng Han〔2026〕273
Target year2030
Core focusTiered diagnosis and treatment; primary care capacity building
Total measures10 specific requirements

The Six Expansions

The directive mandates six structural coverage extensions:

  1. Specialist inclusion — By end-2026, grassroots clinics must deploy internal medicine, pediatrics, and TCM specialists as family doctors; by end-2027, all other clinical specialties join after training.
  2. Hospital integration — By end-2026, all general practitioners at tightly integrated medical consortium lead hospitals must provide contract services via grassroots platforms; by end-2027, physicians stationed at grassroots facilities for over one year must enroll.
  3. Private sector entry — Private institutions with strong capacity and reputation may deliver contract services for elderly, pediatric, and mental health populations via multi-site practice arrangements.
  4. Individual contracts — Shift from team-based to individual physician-patient contracts by end-2027, with the family doctor as the first accountable party.
  5. Disease scope — By end-2027, expand from chronic disease management to combined chronic and infectious disease co-management, including respiratory, gastrointestinal, vector-borne diseases, tuberculosis, and HIV prevention. Family doctors may issue vaccine prescriptions where qualified.
  6. Flexible terms — By end-2026, replace fixed contract cycles with adaptable durations; first-time contracts require face-to-face signing, renewals permitted online.

Key Implementation Timeline

DeadlineRequirement
End-2026Internal medicine, pediatrics, TCM specialists at grassroots clinics enrolled as family doctors; tightly integrated consortium GPs deployed; flexible contract cycles available
End-2027All clinical specialties eligible; stationed hospital physicians enrolled; individual contracts mandated; infectious disease co-management integrated

Additional Directives

  • Gatekeeping mandate — Family doctors assume first-contact responsibility; patients beyond a doctor’s scope are referred within the same institution or upward via consortium green channels, with bidirectional referral IT platforms required.
  • Segmented services — Elderly, children, pregnant women, and disabled groups sign via residence-based clinics; working populations sign via employer-based facilities; family-unit enrollment encouraged.
  • Content optimization — Packages include health education, chronic disease follow-up, pediatric guidance, elderly assessments, medication counseling, TCM constitution identification, dietary therapy, medicinal tea substitutes, and Baduanjin exercise programs.
  • Digital enablement — “AI+” contract services, online renewal/consultation/follow-up/referral, annual “health portraits” integrating electronic records and wearable device data, and real-time health monitoring systems.

Market Impact Analysis

The directive operationalizes Beijing’s broader tiered-care reform by tightening the gatekeeping role of family doctors—a structural pivot designed to divert patient flow from overloaded tertiary hospitals to primary facilities. The inclusion of tier-two and tier-three hospitals alongside private clinics signals a unified primary-care network rather than an isolated grassroots system.

The AI and wearable device mandates are particularly notable. By formally embedding artificial intelligence into family doctor workflows and mandating annual digital health portraits fed by wearable data, regulators are betting on technology to close the capacity gap at the primary level, where physician shortages have historically undermined contract-service quality. If executed at scale, the “AI+” push could reduce administrative burdens on grassroots clinicians and standardize chronic-disease monitoring across provinces.

The TCM integration—constitution identification, medicinal cuisine, and Baduanjin—creates a distinct regulatory moat for domestic traditional medicine providers while potentially limiting market access for foreign device and pharma companies in the primary care segment.

Forward-Looking Statement

Healthcare analysts expect the 10-point plan to accelerate consolidation of China’s primary-care market, creating partnership opportunities for private clinics, health-tech vendors, and wearable device manufacturers that can demonstrate AI-enabled diagnostic or patient-management tools. The mandate for tier-two and tier-three hospital participation may gradually blur institutional boundaries, potentially reshaping referral revenue streams. With the 2030 target date aligning with the 15th Five-Year Plan cycle, the directive sets the regulatory foundation for a nationwide family doctor network that could serve as the data and patient-flow backbone for future value-based care pilots. Pilot zones—including national primary care reform demonstration areas—are expected to roll out implementation templates by mid-2027.-China Health Reform Pulse

Policy Source: https://www.nhc.gov.cn/jws/c100073/202608/b42e53e6d1f54bb293a9b6d8ed25de1e.shtml

China Grants Priority Review to Three Medical Devices, Including Rare Disease Tests

Beijing, Aug 24, 2026 — China’s Center for Medical Device Evaluation (CMDE) unveiled the 17th priority review roster of 2026, clearing three devices for expedited market approval, including diagnostic kits for rare diseases and a clinically urgent oncology biomarker assay.

Priority Review Roster

No.Application No.ProductApplicantPriority Rationale
1CSZ2600245Unconjugated Bilirubin Assay Kit (LC-MS/MS)Shenzhen Huiyun Biotechnology Co., Ltd.Rare disease diagnosis/treatment with significant clinical advantage
2CSZ2600259Claudin18.2 (EPR19202) Antibody Reagent (IHC)Guangzhou Ampere Medical Technology Co., Ltd.Clinically urgent; no equivalent approved in China
3CSZ2600262Leber Hereditary Optic Neuropathy Gene Detection Kit (PCR-Fluorescence Probe)Wenzhou Puxi Gene Technology Co., Ltd.Rare disease diagnosis with clinical advantage; clinically urgent with no domestic equivalent

Regulatory Framework

The designations fall under the Medical Device Priority Review Procedure, which grants accelerated assessment pathways for products meeting criteria such as rare disease relevance, clinical urgency, or absence of approved domestic alternatives. The public comment window runs from Aug 24 to Aug 31, 2026. Stakeholders may file objections via email to gcdivision@cmde.org.cn.

Market Impact Analysis

The roster underscores Beijing’s continued regulatory favor toward rare disease diagnostics and precision oncology tools. Shenzhen Huiyun and Wenzhou Puxi both secured slots via the rare disease pathway—a segment that has drawn intensified policy support as China expands its rare disease catalog and reimbursement frameworks.

Guangzhou Ampere’s Claudin18.2 immunohistochemistry reagent addresses a high-priority oncology target, notably in gastric cancer, where the biomarker has gained global traction as a therapeutic and diagnostic anchor. Securing priority status positions the firm to capture first-mover advantage in a market currently lacking approved domestic equivalents.

For investors, the list offers a near-term indicator of which clinical domains—rare metabolic disorders, hereditary optic neuropathy, and GI oncology—regulators are actively fast-tracking. The concentrated representation of molecular diagnostics (LC-MS/MS, PCR-fluorescence, IHC) also signals CMDE’s comfort with advanced testing platforms in the priority queue.

Forward-Looking Statement

Industry observers expect the rare disease and clinically urgent pathways to dominate upcoming priority review cycles through year-end, as Beijing aligns device regulation with broader pharmaceutical and diagnostic policy goals. Companies with pipelines in hereditary disease genotyping, oncology companion diagnostics, and mass-spectrometry-based assays are likely to benefit from shortened approval timelines, provided they can demonstrate clear clinical superiority or address unmet domestic need. The Aug 31 comment deadline is expected to pass without material objections, allowing the three applicants to advance toward final registration decisions by late 2026 or early 2027.-China Health Reform Pulse

Policy Source: https://www.cmde.org.cn/xwdt/zxyw/20260824160407126.html